Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Top-line results from Phase 3 linaclotide trial for chronic constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC).

3 Nov 2009

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

2 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

New study results of INTUNIV presented at a major psychiatric medical meeting

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today.

31 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

World Journal of Gastroenterology reports a case of metallic foreign body in lower mid-abdomen

Foreign body ingestion is a frequent gastrointestinal emergency. However, long spoon swallowing is a rare event. Most swallowed spoons have been found in the stomach. Previously, there has been no reported case of a long spoon reaching the jejunum.

29 Oct 2009

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.

28 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

Given Imaging Ltd. today announced that new data presented at the American College of Gastroenterology (ACG) 2009 Conference show that by visualizing the small bowel with the PillCam® SB video capsule, physicians can detect the cause of occult gastrointestinal bleeding (OGIB) and adapt how they manage and treat these patients.

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

Video capsule endoscopy is safe for patients with heart devices

A new Mayo Clinic study suggests that video capsule endoscopy (CE), a procedure that uses wireless technology in diagnosing intestinal disease, is safe for patients with heart devices. Wireless electrical gadgets, such as cell phones, have been shown to interfere with implanted heart devices, including pacemakers and defibrillators. This risk has led medical experts to speculate that capsule endoscopy could similarly cause heart devices to fail.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Pregabalin, FDA-approved for neuropathic pain (pain caused by shingles and peripheral neuropathy), effectively reduced abdominal pain and improved sleep in women with adhesions, according to a Henry Ford study.

27 Oct 2009

Abdominal Pain News and Research

Further Reading

Shire's INTUNIV for treating ADHD now available in the U.S.

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Top-line results from Phase 3 linaclotide trial for chronic constipation

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences to present Viread Phase III clinical trial data

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Shire to present key data on ADHD treatments at national psychiatric meeting

New study results of INTUNIV presented at a major psychiatric medical meeting

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

World Journal of Gastroenterology reports a case of metallic foreign body in lower mid-abdomen

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Shire receives European approval for FOSRENOL

Data from Phase II clinical trial of NKTR-118 presented

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

Video capsule endoscopy is safe for patients with heart devices

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Pregabalin reduces abdominal pain and improves sleep in women with adhesions

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News